Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas
Abstract
Objective: To estimate the incidence of meningiomatosis and schwannomatosis, and their familial occurrences and relation to type 2 neurofibromatosis (NF2) in a well-defined population.
Methods: Patients with histologically verified intracranial, spinal, or peripheral schwannomas or meningiomas, who were residents of the Helsinki University Hospital catchment area (population, 1,713,000) from January 1, 1985, to December 31, 1995, were included in the study. The Population Register Center was used to identify relatives of all the patients, and their data were linked further to the Finnish Cancer Registry to find NF2-related tumors. Detailed pedigrees were constructed for the patients with NF2, schwannomatosis, meningiomatosis, patients with relatives with histologically verified schwannomas or meningiomas, and patients younger than 25 years of age at the time of diagnosis.
Results: Approximately 3% (12 of 455) of the schwannoma patients had multiple schwannomas in association with NF2, and 2% (11 of 455) had schwannomatosis without NF2. Two of the patients with schwannomatosis (2 of 11) had familial schwannomatosis. Approximately 1% (7 of 823) of the patients with meningioma had multiple meningiomas in association with NF2, and 4% (29 of 823) had meningiomatosis without NF2. No families with meningiomatosis were found among the 823 patients with meningioma studied. The birth occurrence of NF2 was 1 in 87,410.
Conclusions: The current diagnostic criteria of type 2 neurofibromatosis (NF2) seem valid because NF2 patients were differentiated rather easily from patients with sporadic schwannomatosis and meningiomatosis. Familial meningiomatosis, if it truly exists, is very rare, and familial schwannomatosis is uncommon.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043–1050.
2.
Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603–618.
3.
Parry DM, Eldridge R, Kaiser–Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450–461.
4.
Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880–885.
5.
Louis DN, Ramesh V, Gusella JF. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 1995;5:163–172.
6.
MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathological study. Neurology 1996;46:1072–1079.
7.
Seppälä M, Sainio M, Haltia M, Kinnunen J, Setälä K, Jääskeläinen J. Multiple schwannomas: schwannomatosis or NF2? J Neurosurg 1998;89:36–41.
8.
Jacoby LB, Jones D, Davis K, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 1997;61:1293–1302.
9.
Evans DGR, Mason S, Huson SM, Ponder M, Harding AE, Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry 1997;62:361–366.
10.
Butti G, Assietti R, Casalone R, Paoletti P. Multiple meningiomas: a clinical, surgical, and cytogenetic analysis. Surg Neurol 1989;31:255–260.
11.
Domenicucci M, Santoro A, D’Osvaldo DH, Delfini R, Cantore GP, Guidetti B. Multiple intracranial meningiomas. J Neurosurg 1989;70:41–44.
12.
Wood MW, White RJ, Kernohan JW. One hundred intracranial meningiomas found incidentally at necropsy. J Neuropathol Exp Neurol 1957;16:337–340.
13.
Rausing A, Ybo W, Stenflo J. Intracranial meningiomas: a population study of ten years. Acta Neurol Scand 1970;46:102–110.
14.
Lusins JO, Nakagawa H. Multiple meningiomas evaluated by computer tomography. Neurosurgery 1981;9:137–144.
15.
Maxwell M, Shih S, Galanopoulos T, Hedley–Whyte T, Cosgrove GR. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. J Neurosurg 1998;88:562–569.
16.
Pulst S-M, Rouleau GA, Marineau C, et al. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 1993;43:2096–2098.
17.
Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841–846.
18.
Zülch KJ. Histological typing of tumors of the central nervous system. International histological classification of tumours. Geneva:World Health Organization, 1979.
19.
Kleihues P, Burger PC, Scheithauer BW. Histological typing of the tumours of the central nervous system. Berlin:Springer-Verlag, 1993.
20.
Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 1994;33:365–369.
21.
Gutmann DH, Aylsworth A, Garey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51–57.
22.
Rothman KJ. Modern epidemiology. Boston:Little, Brown, 1986.
23.
NIH.National Institutes of Health consensus development conference statement on neurofibromatosis. Neurofibromatosis Res Newsl 1987;3:3–6.
24.
Wu CL, Thakker N, Neary W, et al. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet 1998;35:973–977.
25.
Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45:1314–1322.
Information & Authors
Information
Published In
Copyright
© 2000.
Publication History
Received: May 26, 1999
Accepted: July 29, 1999
Published online: January 11, 2000
Published in print: January 11, 2000
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Optimal Delivery of Pain Management in Schwannomatosis: A Literature Review, Therapeutics and Clinical Risk Management, Volume 21, (61-68), (2025).https://doi.org/10.2147/TCRM.S362794
- NF2 -related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study , Journal of Medical Genetics, 61, 9, (856-860), (2024).https://doi.org/10.1136/jmg-2024-110065
- Epidemiology, tumour characteristics, treatment and outcomes associated with spinal nerve sheath tumours: a systematic review protocol, BMJ Open, 14, 10, (e083011), (2024).https://doi.org/10.1136/bmjopen-2023-083011
- Clinical course and predictors of outcome following surgical treatment of benign peripheral nerve sheath tumors, a single center retrospective study, International Journal of Neuroscience, (1-7), (2024).https://doi.org/10.1080/00207454.2024.2342977
- Low back pain with axillary mass in a perimenopausal woman: A case of schwannomatosis mimicking metastasis, Radiology Case Reports, 19, 9, (3710-3714), (2024).https://doi.org/10.1016/j.radcr.2024.05.062
- Natural history of hearing and tumor growth in vestibular schwannoma in neurofibromatosis type 2-related schwannomatosis, European Archives of Oto-Rhino-Laryngology, 281, 8, (4175-4182), (2024).https://doi.org/10.1007/s00405-024-08601-4
- Meningiomas in Genetic and Familial Syndromes: Biomolecular Correlations, Meningiomas, (35-41), (2024).https://doi.org/10.1007/978-3-031-76680-0_4
- Neuro-Oculocutaneous Syndromes (Phakomatoses), Clinical Ophthalmic Oncology, (125-150), (2024).https://doi.org/10.1007/978-3-031-72433-6_10
- Rare Solid Pancreatic Lesions on Cross-Sectional Imaging, Diagnostics, 13, 16, (2719), (2023).https://doi.org/10.3390/diagnostics13162719
- Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis, Orphanet Journal of Rare Diseases, 18, 1, (2023).https://doi.org/10.1186/s13023-023-02911-2
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.